It’s well known that many important immune and virological problems have been addressed via using regular model viruses, such as LCMV. Therefore, It is extremely hard, or rare to address critically important immunological issues using hepatitis B virus, but Dr. Li et al. have successfully achieved this goal. Excellently Done! This is not easy but very hard, especially in China. Hope Dr. Li will succeed in anti-viral immunity, and immune tolerance against HBV, or in some importantly pure immunologic issues in his future professional development.
Obviously, there are some valuable experiences for our reference from Dr. Li’s present excellent story. Maybe most important is how to find a good or important scientific problem for tackling.
Personally speaking, HBV has some unique advantages over other common model viruses for resolving some immune issues, such as maintenance or breaking of immune tolerance. I believe HBV is a good model virus for hepatic immunity research at least!
It’s well known that many important immune and virological problems have been addressed via using regular model viruses, such as LCMV. Therefore, It is extremely hard, or rare to address critically important immunological issues using hepatitis B virus, but Dr. Li et al. have successfully achieved this goal. Excellently Done! This is not easy but very hard, especially in China. Hope Dr. Li will succeed in anti-viral immunity, and immune tolerance against HBV, or in some importantly pure immunologic issues in his future professional development.
Obviously, there are some valuable experiences for our reference from Dr. Li’s present excellent story. Maybe most important is how to find a good or important scientific problem for tackling.
Personally speaking, HBV has some unique advantages over other common model viruses for resolving some immune issues, such as maintenance or breaking of immune tolerance. I believe HBV is a good model virus for hepatic immunity research at least!
It’s well known that many important immune and virological problems have been addressed via using regular model viruses, such as LCMV. Therefore, It is extremely hard, or rare to address critically important immunological issues using hepatitis B virus, but Dr. Li et al. have successfully achieved this goal. Excellently Done! This is not easy but very hard, especially in China. Hope Dr. Li will succeed in anti-viral immunity, and immune tolerance against HBV, or in some importantly pure immunologic issues in his future professional development.
Obviously, there are some valuable experiences for our reference from Dr. Li’s present excellent story. Maybe most important is how to find a good or important scientific problem for tackling.
Personally speaking, HBV has some unique advantages over other common model viruses for resolving some immune issues, such as maintenance or breaking of immune tolerance. I believe HBV is a good model virus for hepatic immunity research at least!